{"pmid":32504060,"title":"Immune evasion via SARS-CoV-2 ORF8 protein?","text":["Immune evasion via SARS-CoV-2 ORF8 protein?","Nat Rev Immunol","Park, Matthew D","32504060"],"journal":"Nat Rev Immunol","authors":["Park, Matthew D"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504060","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1038/s41577-020-0360-z","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488334573569,"score":9.490897,"similar":[{"pmid":32397643,"title":"Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.","text":["Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.","The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 respiratory disease pandemic utilizes unique 2'-O-methyltransferase (2'-O-MTase) capping machinery to camouflage its RNA from innate immune recognition. The nsp16 catalytic subunit of the 2'-O-MTase is unusual in its requirement for a stimulatory subunit (nsp10) to catalyze the ribose 2'-O-methylation of the viral RNA cap. Here we provide a computational basis for drug repositioning or de novo drug development based on three differential traits of the intermolecular interactions of the SARS-CoV-2-specific nsp16/nsp10 heterodimer, namely: (1) the S-adenosyl-l-methionine-binding pocket of nsp16, (2) the unique \"activating surface\" between nsp16 and nsp10, and (3) the RNA-binding groove of nsp16. We employed approximately 9000 U.S. Food and Drug Administration (FDA)-approved investigational and experimental drugs from the DrugBank repository for docking virtual screening. After molecular dynamics calculations of the stability of the binding modes of high-scoring nsp16/nsp10-drug complexes, we considered their pharmacological overlapping with functional modules of the virus-host interactome that is relevant to the viral lifecycle, and to the clinical features of COVID-19. Some of the predicted drugs (e.g., tegobuvir, sonidegib, siramesine, antrafenine, bemcentinib, itacitinib, or phthalocyanine) might be suitable for repurposing to pharmacologically reactivate innate immune restriction and antagonism of SARS-CoV-2 RNAs lacking 2'-O-methylation.","Viruses","Encinar, Jose Antonio","Menendez, Javier A","32397643"],"abstract":["The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 respiratory disease pandemic utilizes unique 2'-O-methyltransferase (2'-O-MTase) capping machinery to camouflage its RNA from innate immune recognition. The nsp16 catalytic subunit of the 2'-O-MTase is unusual in its requirement for a stimulatory subunit (nsp10) to catalyze the ribose 2'-O-methylation of the viral RNA cap. Here we provide a computational basis for drug repositioning or de novo drug development based on three differential traits of the intermolecular interactions of the SARS-CoV-2-specific nsp16/nsp10 heterodimer, namely: (1) the S-adenosyl-l-methionine-binding pocket of nsp16, (2) the unique \"activating surface\" between nsp16 and nsp10, and (3) the RNA-binding groove of nsp16. We employed approximately 9000 U.S. Food and Drug Administration (FDA)-approved investigational and experimental drugs from the DrugBank repository for docking virtual screening. After molecular dynamics calculations of the stability of the binding modes of high-scoring nsp16/nsp10-drug complexes, we considered their pharmacological overlapping with functional modules of the virus-host interactome that is relevant to the viral lifecycle, and to the clinical features of COVID-19. Some of the predicted drugs (e.g., tegobuvir, sonidegib, siramesine, antrafenine, bemcentinib, itacitinib, or phthalocyanine) might be suitable for repurposing to pharmacologically reactivate innate immune restriction and antagonism of SARS-CoV-2 RNAs lacking 2'-O-methylation."],"journal":"Viruses","authors":["Encinar, Jose Antonio","Menendez, Javier A"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397643","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/v12050525","keywords":["covid-19","computational screening","drug repurposing","methylation","methyltransferases","molecular docking","molecular dynamics"],"locations":["tegobuvir","sonidegib","siramesine","antrafenine","bemcentinib","itacitinib","phthalocyanine"],"e_drugs":["Lu 28-179","sonidegib","tegobuvir","INCB039110","Methionine","phthalocyanine","Ribose","antrafenine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666714494758289408,"score":51.827766},{"pmid":32289821,"pmcid":"PMC7184484","title":"Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense.","text":["Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense.","Wild mammalian species, including bats, constitute the natural reservoir of Betacoronavirus (including SARS, MERS, and the deadly SARS-CoV-2). Different hosts or host tissues provide different cellular environments, especially different antiviral and RNA modification activities that can alter RNA modification signatures observed in the viral RNA genome. The zinc finger antiviral protein (ZAP) binds specifically to CpG dinucleotides and recruits other proteins to degrade a variety of viral RNA genomes. Many mammalian RNA viruses have evolved CpG deficiency. Increasing CpG dinucleotides in these low-CpG viral genomes in the presence of ZAP consistently leads to decreased viral replication and virulence. Because ZAP exhibits tissue-specific expression, viruses infecting different tissues are expected to have different CpG signatures, suggesting a means to identify viral tissue-switching events. I show that SARS-CoV-2 has the most extreme CpG deficiency in all known Betacoronavirus genomes. This suggests that SARS-CoV-2 may have evolved in a new host (or new host tissue) with high ZAP expression. A survey of CpG deficiency in viral genomes identified a virulent canine coronavirus (Alphacoronavirus) as possessing the most extreme CpG deficiency, comparable to that observed in SARS-CoV-2. This suggests that the canine tissue infected by the canine coronavirus may provide a cellular environment strongly selecting against CpG. Thus, viral surveys focused on decreasing CpG in viral RNA genomes may provide important clues about the selective environments and viral defenses in the original hosts.","Mol Biol Evol","Xia, Xuhua","32289821"],"abstract":["Wild mammalian species, including bats, constitute the natural reservoir of Betacoronavirus (including SARS, MERS, and the deadly SARS-CoV-2). Different hosts or host tissues provide different cellular environments, especially different antiviral and RNA modification activities that can alter RNA modification signatures observed in the viral RNA genome. The zinc finger antiviral protein (ZAP) binds specifically to CpG dinucleotides and recruits other proteins to degrade a variety of viral RNA genomes. Many mammalian RNA viruses have evolved CpG deficiency. Increasing CpG dinucleotides in these low-CpG viral genomes in the presence of ZAP consistently leads to decreased viral replication and virulence. Because ZAP exhibits tissue-specific expression, viruses infecting different tissues are expected to have different CpG signatures, suggesting a means to identify viral tissue-switching events. I show that SARS-CoV-2 has the most extreme CpG deficiency in all known Betacoronavirus genomes. This suggests that SARS-CoV-2 may have evolved in a new host (or new host tissue) with high ZAP expression. A survey of CpG deficiency in viral genomes identified a virulent canine coronavirus (Alphacoronavirus) as possessing the most extreme CpG deficiency, comparable to that observed in SARS-CoV-2. This suggests that the canine tissue infected by the canine coronavirus may provide a cellular environment strongly selecting against CpG. Thus, viral surveys focused on decreasing CpG in viral RNA genomes may provide important clues about the selective environments and viral defenses in the original hosts."],"journal":"Mol Biol Evol","authors":["Xia, Xuhua"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289821","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1093/molbev/msaa094","keywords":["covid-19","sars-cov-2","canine intestine","viral evolution","zinc finger antiviral protein"],"e_drugs":["cytidylyl-3'-5'-guanosine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491388428291,"score":48.144363},{"pmid":32464097,"title":"Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","text":["Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.","Cell Host Microbe","Park, Annsea","Iwasaki, Akiko","32464097"],"abstract":["Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19."],"journal":"Cell Host Microbe","authors":["Park, Annsea","Iwasaki, Akiko"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464097","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.chom.2020.05.008","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521320927232,"score":47.500923},{"pmid":32433742,"title":"Extended ORF8 Gene Region Is Valuable in the Epidemiological Investigation of SARS-similar Coronavirus.","text":["Extended ORF8 Gene Region Is Valuable in the Epidemiological Investigation of SARS-similar Coronavirus.","Severe acute respiratory syndrome Coronavirus (SARS-CoV) was discovered as a novel pathogen in the 2002-2003 SARS epidemic. The emergence and disappearance of this pathogen have brought questions regarding its source and evolution. Within the genome sequences of 281 SARS-CoVs, SARS-CoV-2, and SARSr-CoVs, a ~430 bp genomic region (from 27701bp to 28131bp in AY390556.1) with regular variations was investigated. This ~430 bp region overlaps with the ORF8 gene and is prone to deletions and nucleotide substitutions. Its complexity suggested the need for a new genotyping method for Coronavirus related to SARS-similar Coronavirus (SARS-CoV, SARSr-CoV and SARS-CoV-2). Bat SARSr-CoV presented three genotypes, of which Type 0 is only seen in Bat SARSr-CoV, Type I is present in SARS early phase and Type II is found in all SARS-CoV-2. This genotyping also shows potential usage in distinguishing the SARS-similar Coronaviruses from different hosts and geographic areas. This genomic region has important implications for predicting the epidemic trend and studying the evolution of Coronavirus.","J Infect Dis","Chen, Shuaiyin","Zheng, Xin","Zhu, Jingyuan","Ding, Ronghua","Jin, Yuefei","Zhang, Weiguo","Yang, HaiYan","Zheng, Yingjuan","Li, Xin","Duan, Guangcai","32433742"],"abstract":["Severe acute respiratory syndrome Coronavirus (SARS-CoV) was discovered as a novel pathogen in the 2002-2003 SARS epidemic. The emergence and disappearance of this pathogen have brought questions regarding its source and evolution. Within the genome sequences of 281 SARS-CoVs, SARS-CoV-2, and SARSr-CoVs, a ~430 bp genomic region (from 27701bp to 28131bp in AY390556.1) with regular variations was investigated. This ~430 bp region overlaps with the ORF8 gene and is prone to deletions and nucleotide substitutions. Its complexity suggested the need for a new genotyping method for Coronavirus related to SARS-similar Coronavirus (SARS-CoV, SARSr-CoV and SARS-CoV-2). Bat SARSr-CoV presented three genotypes, of which Type 0 is only seen in Bat SARSr-CoV, Type I is present in SARS early phase and Type II is found in all SARS-CoV-2. This genotyping also shows potential usage in distinguishing the SARS-similar Coronaviruses from different hosts and geographic areas. This genomic region has important implications for predicting the epidemic trend and studying the evolution of Coronavirus."],"journal":"J Infect Dis","authors":["Chen, Shuaiyin","Zheng, Xin","Zhu, Jingyuan","Ding, Ronghua","Jin, Yuefei","Zhang, Weiguo","Yang, HaiYan","Zheng, Yingjuan","Li, Xin","Duan, Guangcai"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433742","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/infdis/jiaa278","keywords":["orf8 gene","sars-cov","sars-cov-2","genotyping method"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1667342288175497216,"score":44.99158},{"pmid":32476574,"title":"Virtual Screening-Driven Drug Discovery of SARS-CoV2 Enzyme Inhibitors Targeting Viral Attachment, Replication, Post-Translational Modification and Host Immunity Evasion Infection Mechanisms.","text":["Virtual Screening-Driven Drug Discovery of SARS-CoV2 Enzyme Inhibitors Targeting Viral Attachment, Replication, Post-Translational Modification and Host Immunity Evasion Infection Mechanisms.","The novel coronavirus SARS-CoV2, the causative agent of the pandemic disease COVID-19, emerged in December 2019 forcing lockdown of communities in many countries. The absence of specific drugs and vaccines, the rapid transmission of the virus, and the increasing number of deaths worldwide necessitated the discovery of new substances for anti-COVID-19 drug development. With the aid of bioinformatics and computational modelling, ninety seven antiviral secondary metabolites from fungi were docked onto five SARS-CoV2 enzymes involved in viral attachment, replication, post-translational modification, and host immunity evasion infection mechanisms followed by molecular dynamics simulation and in silico ADMET prediction (absorption, distribution, metabolism, excretion and toxicity) of the hit compounds. Thus, three fumiquinazoline alkaloids scedapin C (15), quinadoline B (19) and norquinadoline A (20), the polyketide isochaetochromin D1 (8), and the terpenoid 11a-dehydroxyisoterreulactone A (11) exhibited high binding affinities on the target proteins, papain-like protease (PLpro), chymotrypsin-like protease (3CLpro), RNA-directed RNA polymerase (RdRp), non-structural protein 15 (nsp15), and the spike binding domain to GRP78. Molecular dynamics simulation was performed to optimize the interaction and investigate the stability of the top-scoring ligands in complex with the five target proteins. All tested complexes were found to have dynamic stability. Of the five top-scoring metabolites, quinadoline B (19) was predicted to confer favorable ADMET values, high gastrointestinal absorptive probability and poor blood-brain barrier crossing capacities.","J Biomol Struct Dyn","Quimque, Mark Tristan J","Notarte, Kin Israel R","Fernandez, Rey Arturo T","Mendoza, Mark Andrew O","Liman, Rhenz Alfred D","Lim, Justin Allen K","Pilapil, Luis Agustin E","Ong, Jehiel Karsten H","Pastrana, Adriel M","Khan, Abbas","Wei, Dong-Qing","Macabeo, Allan Patrick G","32476574"],"abstract":["The novel coronavirus SARS-CoV2, the causative agent of the pandemic disease COVID-19, emerged in December 2019 forcing lockdown of communities in many countries. The absence of specific drugs and vaccines, the rapid transmission of the virus, and the increasing number of deaths worldwide necessitated the discovery of new substances for anti-COVID-19 drug development. With the aid of bioinformatics and computational modelling, ninety seven antiviral secondary metabolites from fungi were docked onto five SARS-CoV2 enzymes involved in viral attachment, replication, post-translational modification, and host immunity evasion infection mechanisms followed by molecular dynamics simulation and in silico ADMET prediction (absorption, distribution, metabolism, excretion and toxicity) of the hit compounds. Thus, three fumiquinazoline alkaloids scedapin C (15), quinadoline B (19) and norquinadoline A (20), the polyketide isochaetochromin D1 (8), and the terpenoid 11a-dehydroxyisoterreulactone A (11) exhibited high binding affinities on the target proteins, papain-like protease (PLpro), chymotrypsin-like protease (3CLpro), RNA-directed RNA polymerase (RdRp), non-structural protein 15 (nsp15), and the spike binding domain to GRP78. Molecular dynamics simulation was performed to optimize the interaction and investigate the stability of the top-scoring ligands in complex with the five target proteins. All tested complexes were found to have dynamic stability. Of the five top-scoring metabolites, quinadoline B (19) was predicted to confer favorable ADMET values, high gastrointestinal absorptive probability and poor blood-brain barrier crossing capacities."],"journal":"J Biomol Struct Dyn","authors":["Quimque, Mark Tristan J","Notarte, Kin Israel R","Fernandez, Rey Arturo T","Mendoza, Mark Andrew O","Liman, Rhenz Alfred D","Lim, Justin Allen K","Pilapil, Luis Agustin E","Ong, Jehiel Karsten H","Pastrana, Adriel M","Khan, Abbas","Wei, Dong-Qing","Macabeo, Allan Patrick G"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476574","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/07391102.2020.1776639","keywords":["admet","covid-19","sars-cov2","antiviral","fungal natural products","molecular docking","molecular dynamics"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668437835107008512,"score":43.83628}]}